
## Seung-Mo Mo Hong

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6648822/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size. Gut, 2022, 71, 961-973.	12.1	60
2	Real-World Efficacy Data and Predictive Clinical Parameters for Treatment Outcomes in Advanced Esophageal Squamous Cell Carcinoma Treated with Immune Checkpoint Inhibitors. Cancer Research and Treatment, 2022, 54, 505-516.	3.0	17
3	Pancreatic Cysts after Endoscopic Ultrasonography-Guided Ethanol and/or Paclitaxel Ablation Therapy: Another Mimic of Pancreatic Pseudocysts. Pathobiology, 2022, 89, 49-55.	3.8	4
4	Immune profile by multiplexed immunohistochemistry associated with recurrence after chemoradiation in rectal cancer. Journal of Gastroenterology and Hepatology (Australia), 2022, 37, 542-550.	2.8	4
5	Clinicopathological Features and Long-Term Outcomes of Intraductal Papillary Neoplasms of the Bile Duct of the Liver: Single-Institution Experience with 146 Patients. Journal of Gastrointestinal Surgery, 2022, 26, 1394-1405.	1.7	12
6	Liver transplantation in pediatric patients with progressive familial intrahepatic cholestasis: Single center experience of seven cases. Annals of Hepato-biliary-pancreatic Surgery, 2022, 26, 69-75.	0.1	2
7	Granulocytic epithelial lesion (GEL) in heterotopic pancreas. Pancreatology, 2022, 22, 435-442.	1.1	2
8	Double Ki-67 and synaptophysin labeling in pancreatic neuroendocrine tumor biopsies. Pancreatology, 2022, 22, 427-434.	1.1	6
9	The T Category of Distal Extrahepatic Bile Duct Carcinoma. American Journal of Surgical Pathology, 2022, Publish Ahead of Print, .	3.7	0
10	Data Set for Reporting Carcinoma of the Stomach in Gastrectomy. Archives of Pathology and Laboratory Medicine, 2022, 146, 1072-1083.	2.5	5
11	Clinicopathological features and long-term outcomes of intraductal papillary neoplasms of the bile duct of the liver: Single-institution experience with 146 patients. Annals of Hepato-biliary-pancreatic Surgery, 2022, 26, S91-S91.	0.1	0
12	Diagnostic and prognostic impact of fluorodeoxyglucose-positron emission tomography in diagnosing intraductal papillary neoplasms of the bile duct of the liver. Annals of Hepato-biliary-pancreatic Surgery, 2022, 26, S297-S297.	0.1	0
13	Combined Infiltrative Macroscopic Growth Pattern and Infiltrative Microscopic Tumor Border Status Is a Novel Surrogate Marker of Poor Prognosis in Patients With Pancreatic Neuroendocrine Tumor. Archives of Pathology and Laboratory Medicine, 2022, , .	2.5	1
14	Intraductal tubulopapillary neoplasm ( <scp>ITPN</scp> ) of the pancreas: a distinct entity among pancreatic tumors. Histopathology, 2022, 81, 297-309.	2.9	7
15	Pancreatic ductal adenocarcinoma with a predominant large duct pattern has better recurrence-free survival than conventional pancreatic ductal adenocarcinoma: A comprehensive histopathological, immunohistochemical, and mutational study. Human Pathology, 2022, , .	2.0	2
16	Diagnostic and prognostic impact of fluorodeoxyglucose-positron emission tomography in diagnosing intraductal papillary neoplasms of the bile duct of the liver. Annals of Surgical Treatment and Research, 2022, 102, 335.	1.0	5
17	Antibody-mediated blockade for galectin-3 binding protein in tumor secretome abrogates PDAC metastasis. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	5
18	Prognostic implication of SOX2 expression in small intestinal adenocarcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 1049-1060.	2.8	2

#	Article	IF	CITATIONS
19	Distribution pattern of tumor infiltrating lymphocytes and tumor microenvironment composition as prognostic indicators in anorectal malignant melanoma. Modern Pathology, 2021, 34, 141-160.	5.5	9
20	Amsterdam International Consensus Meeting: tumor response scoring in the pathology assessment of resected pancreatic cancer after neoadjuvant therapy. Modern Pathology, 2021, 34, 4-12.	5.5	32
21	CT-determined resectability of borderline resectable and unresectable pancreatic adenocarcinoma following FOLFIRINOX therapy. European Radiology, 2021, 31, 813-823.	4.5	29
22	T2 gallbladder cancer shows substantial survival variation between continents and this is not due to histopathologic criteria or pathologic sampling differences. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 875-884.	2.8	10
23	Tumor Microenvironmental Prognostic Risk in Primary Operable Small Intestinal Adenocarcinoma. American Journal of Surgical Pathology, 2021, 45, 917-929.	3.7	7
24	Post-resection prognosis of patients with hepatic epithelioid hemangioendothelioma. Annals of Surgical Treatment and Research, 2021, 100, 137.	1.0	3
25	Postresection prognosis of combined hepatocellular carcinoma-cholangiocarcinoma according to the 2010 World Health Organization classification: single-center experience of 168 patients. Annals of Surgical Treatment and Research, 2021, 100, 260.	1.0	6
26	Clinicopathological features and post-resection outcomes of inflammatory pseudotumor of the liver. Annals of Hepato-biliary-pancreatic Surgery, 2021, 25, 34-38.	0.1	2
27	Clinicopathological features and post-resection outcomes of hepatocellular adenoma. Annals of Hepato-biliary-pancreatic Surgery, 2021, 25, 25-33.	0.1	2
28	A Clinically Applicable 24-Protein Model for Classifying Risk Subgroups in Pancreatic Ductal Adenocarcinomas using Multiple Reaction Monitoring-Mass Spectrometry. Clinical Cancer Research, 2021, 27, 3370-3382.	7.0	11
29	Large tumor size, lymphovascular invasion, and synchronous metastasis are associated with the recurrence of solid pseudopapillary neoplasms of the pancreas. Hpb, 2021, 23, 220-230.	0.3	18
30	Pancreatic cancer pathology viewed in the light of evolution. Cancer and Metastasis Reviews, 2021, 40, 661-674.	5.9	7
31	Profiling of conditionally reprogrammed cell lines for in vitro chemotherapy response prediction of pancreatic cancer. EBioMedicine, 2021, 65, 103218.	6.1	5
32	Post-resection prognosis of combined hepatocellular carcinoma-cholangiocarcinoma cannot be predicted by the 2019 World Health Organization classification. Asian Journal of Surgery, 2021, 44, 1389-1395.	0.4	3
33	Longâ€ŧerm outcomes of endoscopic papillectomy for earlyâ€stage cancer in duodenal ampullary adenoma: Comparison to surgical treatment. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 2315-2323.	2.8	10
34	A comparison between 25-gauge and 22-gauge Franseen needles for endoscopic ultrasound-guided sampling of pancreatic and peripancreatic masses: a randomized non-inferiority study. Endoscopy, 2021, 53, 1122-1129.	1.8	14
35	Prognosis of hepatic epithelioid hemangioendothelioma after living donor liver transplantation. Korean Journal of Transplantation, 2021, 35, 15-23.	0.1	4
36	Clinicopathological correlation and post-resection outcomes of hepatic angiomyolipoma. Annals of Hepato-biliary-pancreatic Surgery, 2021, 25, 215-220.	0.1	2

#	Article	IF	CITATIONS
37	Downregulation of 5â€hydroxymethylcytosine is an early event in pancreatic tumorigenesis. Journal of Pathology, 2021, 254, 279-288.	4.5	12
38	Reply to Lorenzo et al Endoscopy, 2021, 53, 667-667.	1.8	0
39	Histologic subtyping of ampullary carcinoma for targeted therapy. Journal of Pathology and Translational Medicine, 2021, 55, 235-235.	1.1	0
40	Anchoring the snare tip is a feasible endoscopic mucosal resection method for small rectal neuroendocrine tumors. Scientific Reports, 2021, 11, 12918.	3.3	4
41	Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Pancreatic Cancer: Systematic Review and Still-Open Questions. Cancers, 2021, 13, 3119.	3.7	69
42	Clinicopathological and molecular characterization of chromophobe hepatocellular carcinoma. Liver International, 2021, 41, 2499-2510.	3.9	6
43	Improvement in the Assessment of Response to Preoperative Chemoradiotherapy for Rectal Cancer Using Magnetic Resonance Imaging and a Multigene Biomarker. Cancers, 2021, 13, 3480.	3.7	Ο
44	Colonic Mass Secondary to Sevelamer-associated Rectal Ulcer. Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The, 2021, 78, 72-72.	0.4	0
45	Expression of HER2 and Mismatch Repair Proteins in Surgically Resected Gallbladder Adenocarcinoma. Frontiers in Oncology, 2021, 11, 658564.	2.8	5
46	Pedunculated mucinous cystic neoplasm of the liver. Yeungnam University Journal of Medicine, 2021, , .	1.4	0
47	Feasibility of HER2-Targeted Therapy in Advanced Biliary Tract Cancer: A Prospective Pilot Study of Trastuzumab Biosimilar in Combination with Gemcitabine Plus Cisplatin. Cancers, 2021, 13, 161.	3.7	17
48	Spatial Distribution and Prognostic Implications of Tumor-Infiltrating FoxP3- CD4+ T Cells in Biliary Tract Cancer. Cancer Research and Treatment, 2021, 53, 162-171.	3.0	11
49	Liver transplantation in pediatric patients with progressive familial intrahepatic cholestasis: single center experience of seven cases. Korean Journal of Transplantation, 2021, 35, S149-S149.	0.1	Ο
50	Prognosis of hepatic epithelioid hemangioendothelioma after living donor liver transplantation. Korean Journal of Transplantation, 2021, 35, S151-S151.	0.1	0
51	A Case of Glomus Tumor Mimicking Neuroendocrine Tumor on 68ÂGa-DOTATOC PET/CT. Nuclear Medicine and Molecular Imaging, 2021, 55, 315-319.	1.0	1
52	High YAP and TEAD4 immunolabelings are associated with poor prognosis in patients with gallbladder cancer. Apmis, 2021, 129, 729-742.	2.0	4
53	Prognostic Value of LC3B and p62 Expression in Small Intestinal Adenocarcinoma. Journal of Clinical Medicine, 2021, 10, 5398.	2.4	5
54	The sulfiredoxin-peroxiredoxin redox system regulates the stemness and survival of colon cancer stem cells. Redox Biology, 2021, 48, 102190.	9.0	7

#	Article	IF	CITATIONS
55	Prognostic Significance of Stromal and Intraepithelial Tumor-Infiltrating Lymphocytes in Small Intestinal Adenocarcinoma. American Journal of Clinical Pathology, 2020, 153, 105-118.	0.7	13
56	The diagnostic performance of novel torque technique for endoscopic ultrasoundâ€guided tissue acquisition in solid pancreatic lesions: A prospective randomized controlled trial. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 508-515.	2.8	15
57	4â€1BB Delineates Distinct Activation Status of Exhausted Tumorâ€Infiltrating CD8+ T Cells in Hepatocellular Carcinoma. Hepatology, 2020, 71, 955-971.	7.3	70
58	Three-dimensional visualization of cleared human pancreas cancer reveals that sustained epithelial-to-mesenchymal transition is not required for venous invasion. Modern Pathology, 2020, 33, 639-647.	5.5	47
59	Clinicopathologic analysis of intraductal papillary neoplasm of bile duct: Korean multicenter cohort study. Hpb, 2020, 22, 1139-1148.	0.3	27
60	Clinicopathologic and Prognostic Significance of Gallbladder and Cystic Duct Invasion in Distal Bile Duct Carcinoma. Archives of Pathology and Laboratory Medicine, 2020, 144, 755-763.	2.5	3
61	Prognostic implications of immune classification in a multicentre cohort of patients with small intestinal adenocarcinoma. Pathology, 2020, 52, 228-235.	0.6	6
62	Endoscopic ultrasound-guided radiofrequency ablation of pancreatic microcystic serous cystic neoplasms: a retrospective study. Endoscopy, 2020, 53, 739-743.	1.8	15
63	Chromogranin A Expression in Rectal Neuroendocrine Tumors Is Associated With More Aggressive Clinical Behavior and a Poorer Prognosis. American Journal of Surgical Pathology, 2020, 44, 1496-1505.	3.7	9
64	Prognostic implication of high grade biliary intraepithelial neoplasia in bile duct resection margins in patients with resected perihilar cholangiocarcinoma. Journal of Hepato-Biliary-Pancreatic Sciences, 2020, 27, 604-613.	2.6	4
65	Molecular characterization of organoids derived from pancreatic intraductal papillary mucinous neoplasms. Journal of Pathology, 2020, 252, 252-262.	4.5	30
66	Tumor Budding and Poorly Differentiated Clusters in Small Intestinal Adenocarcinoma. Cancers, 2020, 12, 2199.	3.7	14
67	Comprehensive histological evaluation with clinical analysis of venous invasion in pancreatic ductal adenocarcinoma: From histology to clinical implications. Pancreatology, 2020, 20, 1486-1494.	1.1	5
68	Loss of HES-1 Expression Predicts a Poor Prognosis for Small Intestinal Adenocarcinoma Patients. Frontiers in Oncology, 2020, 10, 1427.	2.8	2
69	Genomic characterization of malignant progression in neoplastic pancreatic cysts. Nature Communications, 2020, 11, 4085.	12.8	77
70	CD117 Is a Specific Marker of Intraductal Papillary Mucinous Neoplasms (IPMN) of the Pancreas, Oncocytic Subtype. International Journal of Molecular Sciences, 2020, 21, 5794.	4.1	15
71	Reply to Comment on "Jun, S.Y.; et al. Tumor Budding and Poorly Differentiated Clusters in Small Intestinal Adenocarcinoma―Cancers 2020, 12, 2199. Cancers, 2020, 12, 2987.	3.7	0
72	Threeâ€dimensional analysis of extrahepatic cholangiocarcinoma and tumor budding. Journal of Pathology, 2020, 251, 400-410.	4.5	16

#	Article	IF	CITATIONS
73	A novel nanoparticle-based theranostic agent targeting LRP-1 enhances the efficacy of neoadjuvant radiotherapy in colorectal cancer. Biomaterials, 2020, 255, 120151.	11.4	27
74	Clinicopathological characteristics of intraductal papillary neoplasm of the bile duct: a Japanâ€Korea collaborative study. Journal of Hepato-Biliary-Pancreatic Sciences, 2020, 27, 581-597.	2.6	37
75	Biliary intraductal tubuleâ€forming neoplasm: a whole exome sequencing study of MUC5ACâ€positive and â€negative cases. Histopathology, 2020, 76, 1005-1012.	2.9	9
76	Pancreatic acinar cell carcinomas and mixed acinar-neuroendocrine carcinomas are more clinically aggressive than grade 1 pancreatic neuroendocrine tumours. Pathology, 2020, 52, 336-347.	0.6	14
77	Luschka Ducts of the Gallbladder in Adults: Case Series Report and Review of the Medical Literature. International Journal of Surgical Pathology, 2020, 28, 482-489.	0.8	4
78	Smooth Muscle Distribution Patterns of Choledochal Cysts and Their Implications for Pathogenesis and Postoperative Complications. American Journal of Clinical Pathology, 2020, 153, 760-771.	0.7	9
79	Comparison between neuroendocrine carcinomas and well-differentiated neuroendocrine tumors of the pancreas using dynamic enhanced CT. European Radiology, 2020, 30, 4772-4782.	4.5	27
80	Clinicopathological significance of olfactomedin-4 in extrahepatic bile duct carcinoma. Pathology Research and Practice, 2020, 216, 152940.	2.3	3
81	A Nine-Gene Signature for Predicting the Response to Preoperative Chemoradiotherapy in Patients with Locally Advanced Rectal Cancer. Cancers, 2020, 12, 800.	3.7	18
82	Tumour-to-liver ratio determined by [68Ga]Ga-DOTA-TOC PET/CT as a prognostic factor of lanreotide efficacy for patients with well-differentiated gastroenteropancreatic-neuroendocrine tumours. EJNMMI Research, 2020, 10, 63.	2.5	22
83	Desmin and CD31 immunolabeling for detecting venous invasion of the pancreatobiliary tract cancers. PLoS ONE, 2020, 15, e0242571.	2.5	10
84	Sarcoma metastasis to the pancreas: experience at a single institution. Journal of Pathology and Translational Medicine, 2020, 54, 220-227.	1.1	7
85	Lymph node size and its association with nodal metastasis in ductal adenocarcinoma of the pancreas. Journal of Pathology and Translational Medicine, 2020, 54, 387-395.	1.1	12
86	Pancreatic High-Grade Neuroendocrine Neoplasms in the Korean Population: A Multicenter Study. Cancer Research and Treatment, 2020, 52, 263-276.	3.0	19
87	Validation of the 8th Edition of the American Joint Committee on Cancer Staging System for Gallbladder Cancer and Implications for the Follow-up of Patients without Node Dissection. Cancer Research and Treatment, 2020, 52, 455-468.	3.0	33
88	Efficacy and Safety of Pembrolizumab in Patients with Refractory Advanced Biliary Tract Cancer: Tumor Proportion Score as a Potential Biomarker for Response. Cancer Research and Treatment, 2020, 52, 594-603.	3.0	55
89	A multimodality test to guide the management of patients with a pancreatic cyst. Science Translational Medicine, 2019, 11, .	12.4	129
90	What Is New in the 2017 World Health Organization Classification and 8th American Joint Committee on Cancer Staging System for Pancreatic Neuroendocrine Neoplasms?. Korean Journal of Radiology, 2019, 20, 5.	3.4	79

#	Article	IF	CITATIONS
91	Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker. European Journal of Cancer, 2019, 120, 31-39.	2.8	58
92	Characterization of Hepatocellular Carcinoma Patients with FGF19 Amplification Assessed by Fluorescence in situ Hybridization: A Large Cohort Study. Liver Cancer, 2019, 8, 12-23.	7.7	27
93	Multiple KRAS mutations in the nonâ€mucinous epithelial lining in the majority of mucinous cystic neoplasms of the pancreas. Histopathology, 2019, 75, 559-567.	2.9	7
94	Analysis of driver somatic mutations in heterotopia of pancreas, spleen, liver and adrenal tissues. Pathology Research and Practice, 2019, 215, 152461.	2.3	0
95	Signet ring cell component predicts aggressive behaviour in colorectal mucinous adenocarcinoma. Pathology, 2019, 51, 384-391.	0.6	38
96	ILâ€33 overexpression in gallbladder cancers associated with pancreatobiliary maljunction. Histopathology, 2019, 75, 365-375.	2.9	9
97	Why is pancreatic cancer so deadly? The pathologist's view. Journal of Pathology, 2019, 248, 131-141.	4.5	76
98	Prognostic comparison of the longitudinal margin status in distal bile duct cancer: R0 on first bile duct resection versus R0 after additional resection. Journal of Hepato-Biliary-Pancreatic Sciences, 2019, 26, 169-178.	2.6	20
99	Prediction of Recurrence With KRAS Mutational Burden Using Ultrasensitive Digital Polymerase Chain Reaction of Radial Resection Margin of Resected Pancreatic Ductal Adenocarcinoma. Pancreas, 2019, 48, 400-411.	1.1	2
100	Efficacy and safety of lanreotide in Korean patients with metastatic, well-differentiated gastroenteropancreatic-neuroendocrine tumors: a retrospective analysis. Investigational New Drugs, 2019, 37, 763-770.	2.6	10
101	Association of SNCA variants with α-synuclein of gastric and colonic mucosa in Parkinson's disease. Parkinsonism and Related Disorders, 2019, 61, 151-155.	2.2	10
102	Detailed pathological analysis of the advancing edge of the tumour can effectively stratify clinical T4b colorectal cancer patients. Histopathology, 2019, 74, 883-891.	2.9	0
103	A "Clearer―View of Pancreatic Pathology: A Review of Tissue Clearing and Advanced Microscopy Techniques. Advances in Anatomic Pathology, 2019, 26, 31-39.	4.3	19
104	High-grade precursor lesions can be used as surrogate markers to identify the epicenter of periampullary carcinomas. Human Pathology, 2019, 84, 92-104.	2.0	3
105	The impact of macroscopic on-site evaluation using filter paper in EUS-guided fine-needle biopsy. Endoscopic Ultrasound, 2019, 8, 342.	1.5	25
106	Coexisting Mucinous Cystic Neoplasm of the Pancreas and Type 1 Autoimmune Pancreatitis. Journal of Pathology and Translational Medicine, 2019, 53, 125-128.	1.1	5
107	Validation of the Eighth American Joint Committee on Cancer Staging System for Distal Bile Duct Carcinoma. Cancer Research and Treatment, 2019, 51, 98-111.	3.0	24
108	Long-term postresection prognosis of primary neuroendocrine tumors of the liver. Annals of Surgical Treatment and Research, 2019, 97, 176.	1.0	9

#	Article	IF	CITATIONS
109	Type 2 Autoimmune Pancreatitis (Idiopathic Duct-Centric Pancreatitis) Highlighting Patients Presenting as Clinical Acute Pancreatitis: A Single-Center Experience. Gut and Liver, 2019, 13, 461-470.	2.9	21
110	Recurrent Pancreatitis Caused by Afferent Loop Syndrome with Pathologic Features of Type II Autoimmune Pancreatitis. Korean Journal of Medicine, 2019, 94, 200-207.	0.3	1
111	Significance of microcystic, elongated, and fragmented glandular-like features in intraductal papillary mucinous neoplasm of the pancreas. Human Pathology, 2018, 78, 18-27.	2.0	2
112	Immunolabeling of Cleared Human Pancreata Provides Insights into Three-Dimensional Pancreatic Anatomy and Pathology. American Journal of Pathology, 2018, 188, 1530-1535.	3.8	38
113	Carbonic anhydrase 9 expression in well-differentiated pancreatic neuroendocrine neoplasms might be associated with aggressive behavior and poor survival. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 472, 739-748.	2.8	12
114	Outcomes after endoscopic ultrasoundâ€guided ethanolâ€lipiodol ablation of small pancreatic neuroendocrine tumors. Digestive Endoscopy, 2018, 30, 652-658.	2.3	39
115	Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis. Investigational New Drugs, 2018, 36, 732-741.	2.6	87
116	Intraductal Papillary Neoplasm of the Bile Duct: Clinical, Imaging, and Pathologic Features. American Journal of Roentgenology, 2018, 211, 67-75.	2.2	69
117	Validation of the eighth edition of the American Joint Committee on Cancer staging system for ampulla of Vater cancer. Surgery, 2018, 163, 1071-1079.	1.9	15
118	A statement by the Japanâ€Korea expert pathologists for future clinicopathological and molecular analyses toward consensus building of intraductal papillary neoplasm of the bile duct through several opinions at the present stage. Journal of Hepato-Biliary-Pancreatic Sciences, 2018, 25, 181-187.	2.6	85
119	MDM2 Amplification in Intrahepatic Cholangiocarcinomas. American Journal of Surgical Pathology, 2018, 42, 512-521.	3.7	21
120	Clinicopathological and prognostic significance of heme oxygenaseâ€4 expression in small intestinal adenocarcinomas. Pathology International, 2018, 68, 294-300.	1.3	7
121	REP1 inhibits FOXO3-mediated apoptosis to promote cancer cell survival. Cell Death and Disease, 2018, 8, e2536-e2536.	6.3	20
122	Xanthogranulomatous cholecystitis shows overlapping histological features with IgG4â€related cholecystitis. Histopathology, 2018, 72, 569-579.	2.9	15
123	FGFR1 expression defines clinically distinct subtypes in pancreatic cancer. Journal of Translational Medicine, 2018, 16, 374.	4.4	18
124	Association Between Expression Level of PD1 by Tumor-Infiltrating CD8+ T Cells and Features of HepatocellularÂCarcinoma. Gastroenterology, 2018, 155, 1936-1950.e17.	1.3	211
125	Grading by the Ki-67 Labeling Index of Endoscopic Ultrasound–Guided Fine Needle Aspiration Biopsy Specimens of Pancreatic Neuroendocrine Tumors Can Be Underestimated. Pancreas, 2018, 47, 1296-1303.	1.1	30
126	Precursor Lesions of Pancreatic Cancer. Oncology Research and Treatment, 2018, 41, 603-610.	1.2	31

#	Article	IF	CITATIONS
127	Dual loss of USP10 and p14ARF protein expression is associated with poor prognosis in patients with small intestinal adenocarcinoma. Tumor Biology, 2018, 40, 101042831880867.	1.8	10
128	Highâ€grade Pan <scp>IN</scp> presenting with localised stricture of the main pancreatic duct: A clinicopathological and molecular study of 10 cases suggests a clue for the early detection of pancreatic cancer. Histopathology, 2018, 73, 247-258.	2.9	34
129	Relation of Enteric α-Synuclein to Gastrointestinal Dysfunction in Patients With Parkinson's Disease and in Neurologically Intact Subjects. Journal of Neurogastroenterology and Motility, 2018, 24, 469-478.	2.4	30
130	JOURNAL CLUB: Primary Anorectal Melanoma: MRI Findings and Clinicopathologic Correlations. American Journal of Roentgenology, 2018, 211, W98-W108.	2.2	13
131	The usefulness of contrast-enhanced harmonic EUS-guided fine-needle aspiration for evaluation of hepatic lesions (withÂvideo). Gastrointestinal Endoscopy, 2018, 88, 495-501.	1.0	25
132	Incidentally detected pancreatic neuroendocrine microadenoma with lymph node metastasis. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 473, 649-653.	2.8	11
133	Imaging and clinical features of xanthogranulomatous pancreatitis: an analysis of 10 cases at a single institution. Abdominal Radiology, 2018, 43, 3349-3356.	2.1	5
134	Genetic and metabolic comparison of orthotopic and heterotopic patient-derived pancreatic-cancer xenografts to the original patient tumors. Oncotarget, 2018, 9, 7867-7881.	1.8	14
135	Prognosis of Pancreatic Cancer Patients with Synchronous or Metachronous Malignancies from Other Organs Is Better than Those with Pancreatic Cancer Only. Cancer Research and Treatment, 2018, 50, 1175-1185.	3.0	17
136	Mucosal nerve of the gallbladder: Anatomical variant or malformation?. Clinical Anatomy, 2017, 30, 558-559.	2.7	0
137	Predicting the Grade of Dysplasia of Pancreatic Cystic Neoplasms Using Cyst Fluid DNA Methylation Markers. Clinical Cancer Research, 2017, 23, 3935-3944.	7.0	63
138	Pattern of extragastric recurrence and the role of abdominal computed tomography in surveillance after endoscopic resection of early gastric cancer: Korean experiences. Gastric Cancer, 2017, 20, 843-852.	5.3	24
139	KRAS and PIK3CA mutations in colorectal adenocarcinomas correlate with aggressive histological features and behavior. Human Pathology, 2017, 65, 21-30.	2.0	27
140	PBRM1 loss is a late event during the development of cholangiocarcinoma. Histopathology, 2017, 71, 375-382.	2.9	18
141	Recent updates on grading and classification of neuroendocrine tumors. Annals of Diagnostic Pathology, 2017, 29, 11-16.	1.3	161
142	<i>DPC4</i> gene expression in primary pancreatic ductal adenocarcinoma: relationship with CT characteristics. British Journal of Radiology, 2017, 90, 20160403.	2.2	5
143	Perivesical cystic duct of the gallbladder. Surgical and Radiologic Anatomy, 2017, 39, 1401-1403.	1.2	1
144	Loss of CADM4 expression is associated with poor prognosis in small intestinal adenocarcinomas. Apmis, 2017, 125, 437-443.	2.0	3

#	Article	IF	CITATIONS
145	IL-8 Expression in Granulocytic Epithelial Lesions of Idiopathic Duct-centric Pancreatitis (Type 2) Tj ETQq1 1 0.784	314 rgBT	Qverlock 1
146	Heterotopic Pancreas of the Gastrointestinal Tract and Associated Precursor and Cancerous Lesions. American Journal of Surgical Pathology, 2017, 41, 833-848.	3.7	47
147	Postâ€resection Prognosis of Combined Hepatocellular Carcinomaâ€Cholangiocarcinoma According to the 2010 WHO Classification. World Journal of Surgery, 2017, 41, 1347-1357.	1.6	19
148	Longterm prognosis of combined hepatocellular carcinomaâ€cholangiocarcinoma following liver transplantation and resection. Liver Transplantation, 2017, 23, 330-341.	2.4	42
149	Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor. Cancer Chemotherapy and Pharmacology, 2017, 79, 139-146.	2.3	28
150	Molecular Imaging of Colorectal Tumors by Targeting Colon Cancer Secreted Protein-2 (CCSP-2). Neoplasia, 2017, 19, 805-816.	5.3	15
151	Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 10202-10207.	7.1	438
152	Clinical outcomes of patients with resectable pancreatic acinar cell carcinoma. Journal of Digestive Diseases, 2017, 18, 480-486.	1.5	14
153	Incipient serous cystic neoplasia of the pancreas is a very rare phenomenon: a systematic prospective observation in pancreatectomy specimens—reply. Human Pathology, 2017, 70, 141-142.	2.0	0
154	Pancreatic intraductal tubulopapillary neoplasm is genetically distinct from intraductal papillary mucinous neoplasm and ductal adenocarcinoma. Modern Pathology, 2017, 30, 1760-1772.	5.5	67
155	A comparison of enhancement patterns on dynamic enhanced CT and survival between patients with pancreatic neuroendocrine tumors with and without intratumoral fibrosis. Abdominal Radiology, 2017, 42, 2835-2842.	2.1	13
156	A strategy for actualization of active targeting nanomedicine practically functioning in a living body. Biomaterials, 2017, 141, 136-148.	11.4	9
157	Establishment and characterization of 6 novel patient-derived primary pancreatic ductal adenocarcinoma cell lines from Korean pancreatic cancer patients. Cancer Cell International, 2017, 17, 47.	4.1	10
158	A primary pure pancreatic-type acinar cell carcinoma of the stomach: a case report. Diagnostic Pathology, 2017, 12, 10.	2.0	15
159	Pancreatic serous cystic neoplasms accompanying other pancreatic tumors. Human Pathology, 2017, 60, 104-113.	2.0	7
160	CD133 expression in well-differentiated pancreatic neuroendocrine tumors: a potential predictor of progressive clinical courses. Human Pathology, 2017, 61, 148-157.	2.0	7
161	Intrahepatic Cholangiocarcinoma in Patients with Cirrhosis: Differentiation from Hepatocellular Carcinoma by Using Gadoxetic Acid–enhanced MR Imaging and Dynamic CT. Radiology, 2017, 282, 771-781.	7.3	73
162	Clinicopathological Features and Postâ€resection Prognosis of Double Primary Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. World Journal of Surgery, 2017, 41, 825-834.	1.6	8

#	Article	IF	CITATIONS
163	Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival. Clinical Cancer Research, 2017, 23, 1598-1606.	7.0	101
164	Preclinical evaluation of cisplatin-incorporated bio-nanocapsules as chemo-radiotherapy for human hepatocellular carcinoma. Oncology Reports, 2017, 38, 2259-2266.	2.6	5
165	Lynch syndrome-related small intestinal adenocarcinomas. Oncotarget, 2017, 8, 21483-21500.	1.8	25
166	Post-Ischemic Bowel Stricture: CT Features in Eight Cases. Korean Journal of Radiology, 2017, 18, 936.	3.4	22
167	Clinicopathological Features and Prognosis of Intrahepatic Cholangiocarcinoma After Liver Transplantation and Resection. Annals of Transplantation, 2017, 22, 42-52.	0.9	15
168	The DPC4/SMAD4 genetic status determines recurrence patterns and treatment outcomes in resected pancreatic ductal adenocarcinoma: A prospective cohort study. Oncotarget, 2017, 8, 17945-17959.	1.8	45
169	Multiplexed gene expression profiling identifies the FGFR4 pathway as a novel biomarker in intrahepatic cholangiocarcinoma. Oncotarget, 2017, 8, 38592-38601.	1.8	21
170	Prediction of radio-responsiveness with immune-profiling in patients with rectal cancer. Oncotarget, 2017, 8, 79793-79802.	1.8	18
171	Endoscopic ultrasound-guided fine-needle aspiration can target right liver mass. Endoscopic Ultrasound, 2017, 6, 109.	1.5	32
172	Loss of Progesterone Receptor Expression Is an Early Tumorigenesis Event Associated with Tumor Progression and Shorter Survival in Pancreatic Neuroendocrine Tumor Patients. Journal of Pathology and Translational Medicine, 2017, 51, 388-395.	1.1	17
173	Paired Primary and Metastatic Tumor Analysis of Somatic Mutations in Synchronous and Metachronous Colorectal Cancer. Cancer Research and Treatment, 2017, 49, 161-167.	3.0	19
174	Postoperative Radiotherapy for Pancreatic Cancer with Microscopically-positive Resection Margin. Anticancer Research, 2017, 37, 755-764.	1.1	3
175	Chronic intractable diarrhea caused by gastrointestinal mastocytosis. Intestinal Research, 2016, 14, 280.	2.6	6
176	Alphaâ€ <b>s</b> ynuclein in gastric and colonic mucosa in Parkinson's disease: Limited role as a biomarker. Movement Disorders, 2016, 31, 241-249.	3.9	69
177	Prognostic factors in 151 patients with surgically resected nonâ€functioning pancreatic neuroendocrine tumours. ANZ Journal of Surgery, 2016, 86, 563-567.	0.7	12
178	Validation of the 2012 International Consensus Guidelines Using Computed Tomography and Magnetic Resonance Imaging. Annals of Surgery, 2016, 263, 557-564.	4.2	76
179	Malignant pancreatic serous cystic neoplasms: systematic review with a new case. BMC Gastroenterology, 2016, 16, 97.	2.0	19
180	Recent Updates on Neuroendocrine Tumors From the Gastrointestinal and Pancreatobiliary Tracts. Archives of Pathology and Laboratory Medicine, 2016, 140, 437-448.	2.5	116

#	Article	IF	CITATIONS
181	Nonductal Pancreatic Cancers. Surgical Pathology Clinics, 2016, 9, 581-593.	1.7	10
182	A melanin-bleaching methodology for molecular and histopathological analysis of formalin-fixed paraffin-embedded tissue. Laboratory Investigation, 2016, 96, 1116-1127.	3.7	17
183	Prognostic Value of Somatostatin Receptor Subtypes in Pancreatic Neuroendocrine Tumors. Pancreas, 2016, 45, 187-192.	1.1	24
184	Postresection Outcomes of Combined Hepatocellular Carcinoma-Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. Journal of Gastrointestinal Surgery, 2016, 20, 411-420.	1.7	74
185	Clinicopathologic and prognostic associations of KRAS and BRAF mutations in small intestinal adenocarcinoma. Modern Pathology, 2016, 29, 402-415.	5.5	31
186	Thread sign in biliary intraductal papillary mucinous neoplasm: a novel specific finding for MRI. European Radiology, 2016, 26, 3112-3120.	4.5	21
187	Hypervascular solid-appearing serous cystic neoplasms of the pancreas: Differential diagnosis with neuroendocrine tumours. European Radiology, 2016, 26, 1348-1358.	4.5	24
188	Prognostic value of CT findings to predict survival outcomes in patients with pancreatic neuroendocrine neoplasms: a single institutional study of 161 patients. European Radiology, 2016, 26, 1320-1329.	4.5	28
189	Clinicopathological Features and Prognosis of Hepatic Epithelioid Hemangioendothelioma After Liver Resection and Transplantation. Annals of Transplantation, 2016, 21, 784-790.	0.9	17
190	Overexpression of <i>ankyrin1</i> promotes pancreatic cancer cell growth. Oncotarget, 2016, 7, 34977-34987.	1.8	18
191	Surgical and Oncological Factors Affecting the Successful Engraftment of Patient-derived Xenografts in Pancreatic Ductal Adenocarcinoma. Anticancer Research, 2016, 36, 517-21.	1.1	19
192	A Revised Classification System and Recommendations From the Baltimore Consensus Meeting for Neoplastic Precursor Lesions in the Pancreas. American Journal of Surgical Pathology, 2015, 39, 1730-1741.	3.7	626
193	Clinicopathologic and Prognostic Significance of Multiple Hormone Expression in Pancreatic Neuroendocrine Tumors. American Journal of Surgical Pathology, 2015, 39, 592-601.	3.7	26
194	Non-L-cell Immunophenotype and Large Tumor Size in Rectal Neuroendocrine Tumors Are Associated With Aggressive Clinical Behavior and Worse Prognosis. American Journal of Surgical Pathology, 2015, 39, 632-643.	3.7	33
195	Heterogeneity of Luschka Ducts of the Gallbladder. Applied Immunohistochemistry and Molecular Morphology, 2015, 23, 674-675.	1.2	1
196	Prognostic Significance of CD44v6, CD133, CD166, and ALDH1 Expression in Small Intestinal Adenocarcinoma. Applied Immunohistochemistry and Molecular Morphology, 2015, 23, 682-688.	1.2	10
197	Prospective Evaluation of New 22 Gauge Endoscopic Ultrasound Core Needle Using Capillary Sampling With Stylet Slow-Pull Technique for Intra-Abdominal Solid Masses. Journal of Clinical Gastroenterology, 2015, 49, 199-205.	2.2	39
198	An unusual presentation of an inflammatory fibroid polyp of the ileum: A case report. Oncology Letters, 2015, 9, 327-329.	1.8	9

#	Article	IF	CITATIONS
199	A Combination of Molecular Markers and Clinical Features Improve the Classification of Pancreatic Cysts. Gastroenterology, 2015, 149, 1501-1510.	1.3	376
200	TFAP2E Methylation Status and Prognosis of Patients with Radically Resected Colorectal Cancer. Oncology, 2015, 88, 122-132.	1.9	17
201	Pyruvate kinase isoenzyme M2 is a therapeutic target of gemcitabine-resistant pancreatic cancer cells. Experimental Cell Research, 2015, 336, 119-129.	2.6	45
202	Intraductal tubulopapillary neoplasms of the bile ducts: clinicopathologic, immunohistochemical, and molecular analysis of 20 cases. Modern Pathology, 2015, 28, 1249-1264.	5.5	85
203	Bleeding from a gastric subepithelial tumor associated with eosinophilia. Gastrointestinal Endoscopy, 2015, 81, 1284-1285.	1.0	1
204	Neuroendocrine neoplasms of the pancreas at dynamic enhanced CT: comparison between grade 3 neuroendocrine carcinoma and grade 1/2 neuroendocrine tumour. European Radiology, 2015, 25, 1375-1383.	4.5	99
205	Granular cell tumor of the gastrointestinal tract: histologic and immunohistochemical analysis of 98 cases. Human Pathology, 2015, 46, 813-819.	2.0	56
206	Gastrointestinal: A case of histologically confirmed scrub typhus gastritis. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 435-435.	2.8	0
207	Type 1 autoimmune pancreatitis with histologically proven granulocytic epithelial lesions. Pancreatology, 2015, 15, 305-307.	1.1	9
208	Heterotopic pancreas of the jejunum: associations between CT and pathology features. Abdominal Imaging, 2015, 40, 38-45.	2.0	26
209	Neuroendocrine neoplasms of the extrahepatic bile duct: radiologic and clinical characteristics. Abdominal Imaging, 2015, 40, 181-191.	2.0	18
210	Clinical and Prognostic Significances of Cytokeratin 19 and KIT Expression in Surgically Resectable Pancreatic Neuroendocrine Tumors. Journal of Pathology and Translational Medicine, 2015, 49, 30-36.	1.1	18
211	S100A4 expression is a prognostic indicator in small intestine adenocarcinoma. Journal of Clinical Pathology, 2014, 67, 216-221.	2.0	8
212	Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies. Science Translational Medicine, 2014, 6, 224ra24.	12.4	3,665
213	Prognostic significance of CDX2 and mucin expression in small intestinal adenocarcinoma. Modern Pathology, 2014, 27, 1364-1374.	5.5	21
214	Solid-pseudopapillary neoplasm of the pancreas in children: Can we predict malignancy?. Journal of Pediatric Surgery, 2014, 49, 1730-1733.	1.6	46
215	Can Statistically Determined Prognostic Factors Predict the Long-Term Survival of Patients With Pancreatic Ductal Adenocarcinoma Following Surgical Resection?. Pancreas, 2014, 43, 571-577.	1.1	17
216	Pancreatic Cancer Induced by In Vivo Electroporation-Enhanced Sleeping Beauty Transposon Gene Delivery System in Mouse. Pancreas, 2014, 43, 614-618.	1.1	13

#	Article	IF	CITATIONS
217	Functional p38 MAPK Identified by Biomarker Profiling of Pancreatic Cancer Restrains Growth through JNK Inhibition and Correlates with Improved Survival. Clinical Cancer Research, 2014, 20, 6200-6211.	7.0	38
218	Increased number of metastatic lymph nodes in adenocarcinoma of the ampulla of Vater as a prognostic factor: A proposal of new nodal classification. Surgery, 2014, 155, 74-84.	1.9	39
219	Prognostic impact of diagnosing colorectal neuroendocrine carcinoma using the World Health Organization 2010 classification. Surgery, 2014, 155, 650-658.	1.9	15
220	Genomic portrait of resectable hepatocellular carcinomas: Implications of <i>RB1</i> and <i>FGF19</i> aberrations for patient stratification. Hepatology, 2014, 60, 1972-1982.	7.3	345
221	Pleomorphic solid pseudopapillary neoplasm of the pancreas: degenerative change rather than high-grade malignant potential. Human Pathology, 2014, 45, 166-174.	2.0	38
222	Survival effect of tumor size and extrapancreatic extension in surgically resected pancreatic cancer: proposal for improved T classification. Human Pathology, 2014, 45, 2341-2346.	2.0	32
223	CT Differentiation of Mucin-Producing Cystic Neoplasms of the Liver From Solitary Bile Duct Cysts. American Journal of Roentgenology, 2014, 202, 83-91.	2.2	35
224	Assessment of vascular endothelial growth factor in formalin fixed, paraffin embedded colon cancer specimens by means of a well-based reverse phase protein array. Proteome Science, 2014, 12, 27.	1.7	9
225	Notch3 signaling is associated with MUC5AC expression and favorable prognosis in patients with small intestinal adenocarcinomas. Pathology Research and Practice, 2014, 210, 501-507.	2.3	6
226	Primary Mesenchymal Tumors of the Pancreas. Pancreas, 2014, 43, 959-968.	1.1	63
227	Epigenetic silencing of EYA2 in pancreatic adenocarcinomas promotes tumor growth. Oncotarget, 2014, 5, 2575-2587.	1.8	29
228	A Small Pancreatic Neuroendocrine Tumor with Marked Pancreatic Duct Dilatation and Parenchymal Atrophy. Korean Journal of Medicine, 2014, 86, 598.	0.3	0
229	Loss of S100A14 Expression Is Associated with the Progression of Adenocarcinomas of the Small Intestine. Pathobiology, 2013, 80, 95-101.	3.8	19
230	Clinical outcomes of rectal neuroendocrine tumors â‰ <b>≇</b> €Š10 mm following endoscopic resection. Endoscopy, 2013, 45, 1018-1023.	1.8	45
231	Genetic Alterations of K-ras, p53, c-erbB-2, and DPC4 in Pancreatic Ductal Adenocarcinoma and Their Correlation With Patient Survival. Pancreas, 2013, 42, 216-222.	1.1	91
232	Combined Loss of E-cadherin and Aberrant β-Catenin Protein Expression Correlates With a Poor Prognosis for Small Intestinal Adenocarcinomas. American Journal of Clinical Pathology, 2013, 139, 167-176.	0.7	34
233	Comparative meta-analysis between human and mouse cancer microarray data reveals critical pathways. International Journal of Data Mining and Bioinformatics, 2013, 8, 349.	0.1	3
234	DPC4 Expression in the Small Intestinal Adenocarcinomas. Korean Journal of Pathology, 2012, 46, 415.	1.3	1

#	Article	IF	CITATIONS
235	Genome-Wide CpG Island Profiling of Intraductal Papillary Mucinous Neoplasms of the Pancreas. Clinical Cancer Research, 2012, 18, 700-712.	7.0	69
236	Genome-Wide Somatic Copy Number Alterations in Low-Grade PanINs and IPMNs from Individuals with a Family History of Pancreatic Cancer. Clinical Cancer Research, 2012, 18, 4303-4312.	7.0	43
237	Molecular Determinants of Retinoic Acid Sensitivity in Pancreatic Cancer. Clinical Cancer Research, 2012, 18, 280-289.	7.0	59
238	Vascular Invasion in Infiltrating Ductal Adenocarcinoma of the Pancreas Can Mimic Pancreatic Intraepithelial Neoplasia. American Journal of Surgical Pathology, 2012, 36, 235-241.	3.7	44
239	Clinicopathological Characteristics and Molecular Analyses of Multifocal Intraductal Papillary Mucinous Neoplasms of the Pancreas. Annals of Surgery, 2012, 255, 326-333.	4.2	112
240	HER3 overexpression is a prognostic indicator of extrahepatic cholangiocarcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 461, 521-530.	2.8	25
241	Intraductal administration of a polymeric nanoparticle formulation of curcumin (NanoCurc) significantly attenuates incidence of mammary tumors in a rodent chemical carcinogenesis model: Implications for breast cancer chemoprevention in at-risk populations. Carcinogenesis, 2012, 33, 2242-2249.	2.8	53
242	MicroRNA Alterations of Pancreatic Intraepithelial Neoplasias. Clinical Cancer Research, 2012, 18, 981-992.	7.0	198
243	Long-term clinical outcome of the surgically resected intraductal papillary neoplasm of the bile duct. Journal of Hepatology, 2012, 57, 787-793.	3.7	96
244	Loss of expression of the SWI/SNF chromatin remodeling subunit BRG1/SMARCA4 is frequently observed in intraductal papillary mucinous neoplasms of the pancreas. Human Pathology, 2012, 43, 585-591.	2.0	56
245	Presence of Somatic Mutations in Most Early-Stage Pancreatic Intraepithelial Neoplasia. Gastroenterology, 2012, 142, 730-733.e9.	1.3	568
246	Unlike Pancreatic Cancer Cells Pancreatic Cancer Associated Fibroblasts Display Minimal Gene Induction after 5-Aza-2′-Deoxycytidine. PLoS ONE, 2012, 7, e43456.	2.5	24
247	A Polymeric Nanoparticle Encapsulated Small-Molecule Inhibitor of Hedgehog Signaling (NanoHHI) Bypasses Secondary Mutational Resistance to Smoothened Antagonists. Molecular Cancer Therapeutics, 2012, 11, 165-173.	4.1	77
248	Elevated microRNA miR-21 Levels in Pancreatic Cyst Fluid Are Predictive of Mucinous Precursor Lesions of Ductal Adenocarcinoma. Pancreatology, 2011, 11, 343-350.	1.1	103
249	Presence of Pancreatic Intraepithelial Neoplasia in the Pancreatic Transection Margin does not Influence Outcome in Patients with RO Resected Pancreatic Cancer. Annals of Surgical Oncology, 2011, 18, 3493-3499.	1.5	62
250	Prevalence of the Alternative Lengthening of Telomeres Telomere Maintenance Mechanism in Human Cancer Subtypes. American Journal of Pathology, 2011, 179, 1608-1615.	3.8	423
251	Pdx1 Expression in Pancreatic Precursor Lesions and Neoplasms. Applied Immunohistochemistry and Molecular Morphology, 2011, 19, 444-449.	1.2	55
252	Gastric Micropapillary Carcinoma. American Journal of Surgical Pathology, 2011, 35, 84-91.	3.7	43

#	Article	IF	CITATIONS
253	Membranous expression of Her3 is associated with a decreased survival in head and neck squamous cell carcinoma. Journal of Translational Medicine, 2011, 9, 126.	4.4	59
254	Telomeres are shortened in acinar-to-ductal metaplasia lesions associated with pancreatic intraepithelial neoplasia but not in isolated acinar-to-ductal metaplasias. Modern Pathology, 2011, 24, 256-266.	5.5	34
255	Loss of E-cadherin expression and outcome among patients with resectable pancreatic adenocarcinomas. Modern Pathology, 2011, 24, 1237-1247.	5.5	90
256	Genome-Wide Analysis of Promoter Methylation Associated with Gene Expression Profile in Pancreatic Adenocarcinoma. Clinical Cancer Research, 2011, 17, 4341-4354.	7.0	154
257	Hilar Cholangiocarcinoma. Archives of Surgery, 2011, 146, 697.	2.2	46
258	Molecular Signatures of Pancreatic Cancer. Archives of Pathology and Laboratory Medicine, 2011, 135, 716-727.	2.5	130
259	In vivo and in vitro propagation of intraductal papillary mucinous neoplasms. Laboratory Investigation, 2010, 90, 665-673.	3.7	14
260	Cyclooxygenase-Deficient Pancreatic Cancer Cells Use Exogenous Sources of Prostaglandins. Molecular Cancer Research, 2010, 8, 821-832.	3.4	27
261	Prognostic Significance of Tumorigenic Cells With Mesenchymal Features in Pancreatic Adenocarcinoma. Journal of the National Cancer Institute, 2010, 102, 340-351.	6.3	392
262	Pancreatic Cancers Epigenetically Silence <i>SIP1</i> and Hypomethylate and Overexpress <i>miR-200a/200b</i> in Association with Elevated Circulating <i>miR-200a</i> and <i>miR-200b</i> Levels. Cancer Research, 2010, 70, 5226-5237.	0.9	268
263	Overexpression of Smoothened Activates the Sonic Hedgehog Signaling Pathway in Pancreatic Cancer–Associated Fibroblasts. Clinical Cancer Research, 2010, 16, 1781-1789.	7.0	159
264	Pancreatic cancer <i>DNMT1</i> expression and sensitivity to <i>DNMT1</i> inhibitors. Cancer Biology and Therapy, 2010, 9, 321-329.	3.4	54
265	Inhibiting the Cyclin-Dependent Kinase CDK5 Blocks Pancreatic Cancer Formation and Progression through the Suppression of Ras-Ral Signaling. Cancer Research, 2010, 70, 4460-4469.	0.9	140
266	The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma. Cancer Biology and Therapy, 2010, 10, 1009-1018.	3.4	85
267	Aberrant MicroRNA-155 Expression Is an Early Event in the Multistep Progression of Pancreatic Adenocarcinoma. Pancreatology, 2010, 10, 66-73.	1.1	116
268	Adenocarcinoma of the small intestine: a multi-institutional study of 197 surgically resected cases. Human Pathology, 2010, 41, 1087-1096.	2.0	75
269	Systemic Administration of Polymeric Nanoparticle-Encapsulated Curcumin (NanoCurc) Blocks Tumor Growth and Metastases in Preclinical Models of Pancreatic Cancer. Molecular Cancer Therapeutics, 2010, 9, 2255-2264.	4.1	184

270 Meta-analysis of cancer microarray data reveals signaling pathway hotspots. , 2009, , .

0

#	Article	IF	CITATIONS
271	Absence of Deleterious Palladin Mutations in Patients with Familial Pancreatic Cancer: Table 1 Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 1328-1330.	2.5	39
272	The Expression of Phospho-AKT, Phospho-mTOR, and PTEN in Extrahepatic Cholangiocarcinoma. Clinical Cancer Research, 2009, 15, 660-667.	7.0	103
273	MicroRNA miR-155 is a biomarker of early pancreatic neoplasia. Cancer Biology and Therapy, 2009, 8, 340-346.	3.4	288
274	Serum Fatty Acid Synthase as a Marker of Pancreatic Neoplasia. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2380-2385.	2.5	81
275	<i>KRAS2</i> Mutations in Human Pancreatic Acinar-Ductal Metaplastic Lesions Are Limited to Those with PanIN: Implications for the Human Pancreatic Cancer Cell of Origin. Molecular Cancer Research, 2009, 7, 230-236.	3.4	98
276	Depth of tumor invasion better predicts prognosis than the current American Joint Committee on Cancer T classification for distal bile duct carcinoma. Surgery, 2009, 146, 250-257.	1.9	119
277	Widespread activation of the DNA damage response in human pancreatic intraepithelial neoplasia. Modern Pathology, 2009, 22, 1439-1445.	5.5	37
278	Extrahepatic Bile Duct Carcinoma: Role of the p53 Protein Family. , 2009, , 441-449.		0
279	Intraductal papillary neoplasm of the bile duct associated with Clonorchis sinensis infection. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2008, 453, 589-598.	2.8	63
280	Multiple genes are hypermethylated in intraductal papillary mucinous neoplasms of the pancreas. Modern Pathology, 2008, 21, 1499-1507.	5.5	79
281	Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses. Science, 2008, 321, 1801-1806.	12.6	3,755
282	Median Regression Tree for Analysis of Censored Survival Data. IEEE Transactions on Systems, Man and Cybernetics, Part A: Systems and Humans, 2008, 38, 715-726.	2.9	10
283	Genome-wide profiling at methylated promoters in pancreatic adenocarcinoma. Cancer Biology and Therapy, 2008, 7, 1146-1156.	3.4	165
284	Pancreatic cancer associated fibroblasts display normal allelotypes. Cancer Biology and Therapy, 2008, 7, 882-888.	3.4	76
285	Genetic and Epigenetic Alterations of Familial Pancreatic Cancers. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 3536-3542.	2.5	79
286	Serial Analysis of Gene Expression Identifies Connective Tissue Growth Factor Expression as a Prognostic Biomarker in Gallbladder Cancer. Clinical Cancer Research, 2008, 14, 2631-2638.	7.0	40
287	Adenosquamous carcinoma of extrahepatic bile duct: clinicopathologic study of 12 cases. International Journal of Clinical and Experimental Pathology, 2008, 1, 147-56.	0.5	19
288	Measurement of the Invasion Depth of Extrahepatic Bile Duct Carcinoma. American Journal of Surgical Pathology, 2007, 31, 199-206.	3.7	60

#	Article	IF	CITATIONS
289	Clinical and prognostic significances of nuclear and cytoplasmic KIT expressions in extrahepatic bile duct carcinomas. Modern Pathology, 2007, 20, 562-569.	5.5	21
290	Biliary intraepithelial neoplasia: an international interobserver agreement study and proposal for diagnostic criteria. Modern Pathology, 2007, 20, 701-709.	5.5	271
291	p63 and p73 expression in extrahepatic bile duct carcinoma and their clinical significance. Journal of Molecular Histology, 2007, 38, 167-175.	2.2	19
292	Expression of Calcium-Binding Proteins S100A2, S100A4 in Barrett's Adenocarcinomas. Neoplasia, 2006, 8, 843-850.	5.3	32
293	Invasive colorectal micropapillary carcinoma: an aggressive variant of adenocarcinoma. Human Pathology, 2006, 37, 809-815.	2.0	94
294	Reconsideration of the Histologic Definitions Used in the Pathologic Staging of Extrahepatic Bile Duct Carcinoma. American Journal of Surgical Pathology, 2006, 30, 744-749.	3.7	19
295	Promoter Hypermethylation of the <i>p16</i> Gene and Loss of Its Protein Expression Is Correlated With Tumor Progression in Extrahepatic Bile Duct Carcinomas. Archives of Pathology and Laboratory Medicine, 2006, 130, 33-38.	2.5	16
296	The Number of Metastatic Lymph Nodes in Extrahepatic Bile Duct Carcinoma as a Prognostic Factor. American Journal of Surgical Pathology, 2005, 29, 1177-1183.	3.7	55
297	Superficial vs deep pancreatic parenchymal invasion in the extrahepatic bile duct carcinomas: a significant prognostic factor. Modern Pathology, 2005, 18, 969-975.	5.5	19
298	Analysis of extrahepatic bile duct carcinomas according to the New American Joint Committee on Cancer staging system focused on tumor classification problems in 222 patients. Cancer, 2005, 104, 802-810.	4.1	55
299	AP-2Î <sup>3</sup> Protein Expression in Intratubular Germ Cell Neoplasia of Testis. American Journal of Clinical Pathology, 2005, 124, 873-877.	0.7	8
300	Neuroendocrine differentiation in extrahepatic bile duct carcinomas and its prognostic significance. Human Pathology, 2005, 36, 732-740.	2.0	22
301	CDX2 and MUC2 Protein Expression in Extrahepatic Bile Duct Carcinoma. American Journal of Clinical Pathology, 2005, 124, 361-370.	0.7	28
302	AP-2gamma protein expression in intratubular germ cell neoplasia of testis. American Journal of Clinical Pathology, 2005, 124, 873-7.	0.7	1
303	Keratosis Lichenoides Chronica: Marked Response to Calcipotriol Ointment. Journal of Dermatology, 2000, 27, 123-126.	1.2	23
304	Smooth Muscle Distribution in the Extrahepatic Bile Duct. American Journal of Surgical Pathology, 2000, 24, 660-667.	3.7	36
305	Prediction of Marginâ€Negative Resection of Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Therapy: Diagnostic Performance of NCCN Criteria for Resection vs. CTâ€Đetermined Resectability. Journal of Hepato-Biliary-Pancreatic Sciences, 0, , .	2.6	1
306	Extranodal extension influences prognosis in pancreatic head cancer: A retrospective cohort study. Journal of Hepato-Biliary-Pancreatic Sciences, 0, , .	2.6	0